EP1379132A4 - Proteines secretees humaines - Google Patents

Proteines secretees humaines

Info

Publication number
EP1379132A4
EP1379132A4 EP02760994A EP02760994A EP1379132A4 EP 1379132 A4 EP1379132 A4 EP 1379132A4 EP 02760994 A EP02760994 A EP 02760994A EP 02760994 A EP02760994 A EP 02760994A EP 1379132 A4 EP1379132 A4 EP 1379132A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02760994A
Other languages
German (de)
English (en)
Other versions
EP1379132A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1379132A2 publication Critical patent/EP1379132A2/fr
Publication of EP1379132A4 publication Critical patent/EP1379132A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02760994A 2001-03-21 2002-03-19 Proteines secretees humaines Withdrawn EP1379132A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008278 WO2002102994A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Publications (2)

Publication Number Publication Date
EP1379132A2 EP1379132A2 (fr) 2004-01-14
EP1379132A4 true EP1379132A4 (fr) 2009-07-01

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02760994A Withdrawn EP1379132A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02759068A Withdrawn EP1404702A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02782476A Withdrawn EP1414845A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02749512A Withdrawn EP1381622A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
EP02799146A Withdrawn EP1390390A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02780789A Withdrawn EP1423134A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
EP02723499A Withdrawn EP1379264A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees

Family Applications After (6)

Application Number Title Priority Date Filing Date
EP02759068A Withdrawn EP1404702A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02782476A Withdrawn EP1414845A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02749512A Withdrawn EP1381622A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
EP02799146A Withdrawn EP1390390A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02780789A Withdrawn EP1423134A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
EP02723499A Withdrawn EP1379264A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees

Country Status (4)

Country Link
EP (7) EP1379132A4 (fr)
AU (6) AU2002320013A1 (fr)
CA (7) CA2441840A1 (fr)
WO (7) WO2003004622A2 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
PT1086223E (pt) 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO2000042073A1 (fr) 1999-01-15 2000-07-20 Biogen, Inc. Antagonistes de la proteine tweak et du recepteur de tweak, et leur utilisation pour traiter des affections immunitaires
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1364021A2 (fr) 2000-10-31 2003-11-26 Diadexus, Inc. Compositions et methodes associees a des genes et a des proteines specifiques du colon
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
US7736654B2 (en) * 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (es) 2001-09-06 2015-03-31 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
WO2003033727A1 (fr) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Procede de criblage d'un inhibiteur de la mort cellulaire
CA2887716C (fr) 2002-04-09 2017-01-24 Biogen Idec Ma Inc. Procede pour traiter les etats lies a tweak
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1670947B1 (fr) 2003-09-23 2015-04-01 University Of North Carolina At Chapel Hill Technique et composition de correlation de polymorphisme nucleotidique simple dans le gene vitamine k epoxyde reductase et le dosage de warfarine
JP4777251B2 (ja) * 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
EP1714154A2 (fr) * 2004-02-03 2006-10-25 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
WO2006026808A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
JP2008512099A (ja) * 2004-09-07 2008-04-24 テレソン インスティテュート フォー チャイルド ヘルス リサーチ アレルギー性疾患の処置または予防のための物質
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CN101124320A (zh) 2005-02-28 2008-02-13 巴克斯特国际公司 重组共表达维生素k环氧化物还原酶亚基1以提高依赖维生素k的蛋白质表达
EP1861499A4 (fr) 2005-03-15 2008-09-03 Univ North Carolina Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US20090054307A1 (en) * 2005-09-01 2009-02-26 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CA2680832A1 (fr) * 2007-03-27 2008-10-02 Merck & Co., Inc. Procede de detection de pcsk9 secretee, autogeneree
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JP5749492B2 (ja) 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物
CA2707182C (fr) * 2007-11-30 2017-12-12 Siemens Healthcare Diagnostics Inc. Fragments de recepteur de l'adiponectine et leurs procedes d'utilisation
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2010068526A1 (fr) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
BR112012032240A2 (pt) 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2012088222A2 (fr) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
AU2017382323B2 (en) 2016-12-23 2024-06-13 President And Fellows Of Harvard College Gene editing of PCSK9
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
EP3642383B1 (fr) 2017-06-22 2022-12-21 The Procter & Gamble Company Films comprenant une couche hydrosoluble et un revêtement inorganique déposé en phase vapeur
EP3641951B1 (fr) 2017-06-22 2023-09-20 The Procter & Gamble Company Films comprenant une couche hydrosoluble et un revêtement organique déposé en phase vapeur
WO2021207711A2 (fr) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Arn guides modifiés chimiquement pour l'édition du génome avec cas9

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees

Also Published As

Publication number Publication date
CA2441755A1 (fr) 2003-05-08
AU2002326293A1 (en) 2003-01-02
WO2002095010A3 (fr) 2004-02-12
AU2002320013A1 (en) 2002-11-18
EP1404702A2 (fr) 2004-04-07
WO2002095010A2 (fr) 2002-11-28
EP1414845A4 (fr) 2009-07-08
AU2002324424A1 (en) 2002-12-03
EP1414845A2 (fr) 2004-05-06
AU2002363296A1 (en) 2003-05-12
EP1381622A2 (fr) 2004-01-21
EP1379264A1 (fr) 2004-01-14
CA2441840A1 (fr) 2002-11-28
EP1379264A4 (fr) 2009-07-08
WO2003004622A2 (fr) 2003-01-16
CA2441417A1 (fr) 2002-11-14
CA2441832A1 (fr) 2002-12-27
WO2003038063A3 (fr) 2003-12-11
WO2002102993A3 (fr) 2004-03-25
CA2441702A1 (fr) 2002-12-27
EP1390390A2 (fr) 2004-02-25
EP1379132A2 (fr) 2004-01-14
WO2003038063A2 (fr) 2003-05-08
WO2002102994A2 (fr) 2002-12-27
EP1390390A4 (fr) 2009-07-08
WO2002102994A3 (fr) 2003-07-24
WO2002090526A2 (fr) 2002-11-14
AU2002354719A1 (en) 2003-01-21
CA2441397A1 (fr) 2002-10-03
EP1423134A2 (fr) 2004-06-02
EP1404702A4 (fr) 2009-07-08
WO2002076488A1 (fr) 2002-10-03
WO2003004622A3 (fr) 2004-02-19
AU2002332391A1 (en) 2003-01-02
CA2441416A1 (fr) 2003-01-16
WO2002102993A2 (fr) 2002-12-27
WO2002090526A3 (fr) 2003-10-30

Similar Documents

Publication Publication Date Title
EP1404702A4 (fr) Proteines secretees humaines
EP1385381A4 (fr) Proteines humaines secretees
EP1251863A4 (fr) 22 proteines humaines secretees
AU2002361452A8 (en) Secreted proteins
GB0218205D0 (en) Human ZZAP1 protein
IL162598A0 (en) Secreted protein
AU2002232596A1 (en) Secreted human proteins
AU2002354803A8 (en) Secreted proteins
EP1368468A4 (fr) 83 proteines humaines secretes
AU2003301843A8 (en) 157 human secreted proteins
EP1385977A4 (fr) Proteines secretees
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (fr) 70 proteines humaines secretees
EP1417224A4 (fr) Proteines secretees
AU2002365153A1 (en) 41 human secreted proteins
EP1404807A4 (fr) 20 proteines humaines secretees
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A8 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2002303843A8 (en) Secreted proteins
AU2003211136A8 (en) 6 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
AU2002253985A1 (en) 83 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
EP1443818A4 (fr) Proteines secretees et utilisations associees

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20090527BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090903